Zhejiang Shouxiangu Pharm Co Cash Flow Conversion Efficiency
Zhejiang Shouxiangu Pharm Co cash flow conversion efficiency. Based on the latest financial reports, Zhejiang Shouxiangu Pharm Co (603896) has a cash flow conversion efficiency ratio of 0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥20.94 Million ≈ $3.06 Million USD) by net assets (CN¥2.31 Billion ≈ $338.43 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Zhejiang Shouxiangu Pharm Co (2012–2025)
Cash flow conversion efficiency of Zhejiang Shouxiangu Pharm Co from 2012 to 2025. This chart illustrates how Zhejiang Shouxiangu Pharm Co's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Zhejiang Shouxiangu Pharm Co stock price today for real-time trading data and today's change.
Zhejiang Shouxiangu Pharm Co Cash Flow Conversion Ratio Explained
Zhejiang Shouxiangu Pharm Co cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Zhejiang Shouxiangu Pharm Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhejiang Shouxiangu Pharm Co ranked by their cash flow conversion efficiency. Also see 603896 stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Future Generation Australia Ltd
AU:FGX
|
0.095x |
|
GWA Group Ltd
AU:GWA
|
0.116x |
|
Malibu Boats Inc
NASDAQ:MBUU
|
0.051x |
|
Tronox Holdings PLC
NYSE:TROX
|
0.084x |
|
First Carolina Financial Services, Inc.
NYSE:FCBM
|
0.014x |
|
Shanghai Jinfeng Wine Co Ltd
SHG:600616
|
0.004x |
|
Hailun Piano Co Ltd
SHE:300329
|
0.006x |
|
BENZ MINING CORP CDI/1
F:1VU0
|
-0.404x |
Annual Cash Flow Conversion Efficiency for Zhejiang Shouxiangu Pharm Co (2012–2025)
The table below shows the annual cash flow conversion efficiency of Zhejiang Shouxiangu Pharm Co from 2012 to 2025. Review Zhejiang Shouxiangu Pharm Co free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.26 Billion ≈ $330.77 Million |
CN¥228.07 Million ≈ $33.37 Million |
0.101x | +8.44% |
| 2024-12-31 | CN¥2.29 Billion ≈ $335.69 Million |
CN¥213.44 Million ≈ $31.23 Million |
0.093x | -35.88% |
| 2023-12-31 | CN¥2.17 Billion ≈ $317.73 Million |
CN¥315.06 Million ≈ $46.10 Million |
0.145x | -18.98% |
| 2022-12-31 | CN¥1.91 Billion ≈ $278.84 Million |
CN¥341.28 Million ≈ $49.94 Million |
0.179x | -2.21% |
| 2021-12-31 | CN¥1.62 Billion ≈ $237.06 Million |
CN¥296.70 Million ≈ $43.42 Million |
0.183x | -5.25% |
| 2020-12-31 | CN¥1.33 Billion ≈ $194.08 Million |
CN¥256.36 Million ≈ $37.51 Million |
0.193x | +9.00% |
| 2019-12-31 | CN¥1.17 Billion ≈ $171.57 Million |
CN¥207.92 Million ≈ $30.42 Million |
0.177x | +1.82% |
| 2018-12-31 | CN¥984.74 Million ≈ $144.10 Million |
CN¥171.51 Million ≈ $25.10 Million |
0.174x | +36.71% |
| 2017-12-31 | CN¥869.75 Million ≈ $127.27 Million |
CN¥110.80 Million ≈ $16.21 Million |
0.127x | -41.72% |
| 2016-12-31 | CN¥436.93 Million ≈ $63.94 Million |
CN¥95.52 Million ≈ $13.98 Million |
0.219x | -5.25% |
| 2015-12-31 | CN¥368.53 Million ≈ $53.93 Million |
CN¥85.03 Million ≈ $12.44 Million |
0.231x | -28.12% |
| 2014-12-31 | CN¥320.56 Million ≈ $46.91 Million |
CN¥102.90 Million ≈ $15.06 Million |
0.321x | +45.99% |
| 2013-12-31 | CN¥299.50 Million ≈ $43.83 Million |
CN¥65.85 Million ≈ $9.64 Million |
0.220x | -32.93% |
| 2012-12-31 | CN¥138.37 Million ≈ $20.25 Million |
CN¥45.36 Million ≈ $6.64 Million |
0.328x | -- |
About Zhejiang Shouxiangu Pharm Co
Zhejiang Shouxiangu Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the breeding, cultivation, processing, and sale of Chinese medicinal herbs in China and internationally. The company offers ganoderma lucidum spore powder, dendrobium officinale, and saffron products, as well as health and ordinary food, agricultural and sideline products, personal and skincare, and tradition… Read more